The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 1, Pages 131-142
Publisher
Informa Healthcare
Online
2014-12-08
DOI
10.1517/14712598.2015.983897
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
- (2014) Georgina Tzanakaki et al. BMC MICROBIOLOGY
- Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study
- (2014) Natalie G Martin et al. LANCET INFECTIOUS DISEASES
- A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty
- (2014) Sophie M Andrews et al. LANCET INFECTIOUS DISEASES
- Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age
- (2014) Fiona McQuaid et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
- (2014) H. Christensen et al. BMJ-British Medical Journal
- A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)
- (2014) Roman Prymula et al. Human Vaccines & Immunotherapeutics
- Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
- (2013) M. D. Snape et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Prolonged University Outbreak of Meningococcal Disease Associated With a Serogroup B Strain Rarely Seen in the United States
- (2013) Sema Mandal et al. CLINICAL INFECTIOUS DISEASES
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- (2013) Ulrich Vogel et al. LANCET INFECTIOUS DISEASES
- Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses
- (2013) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact
- (2013) Hannah Christensen et al. VACCINE
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
- (2013) Giacomo Frosi et al. VACCINE
- Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
- (2013) Julie A. Bettinger et al. VACCINE
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
- (2013) Maria Elena Santolaya et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of vaccination against meningococcal B among Dutch infants
- (2013) Koen B. Pouwels et al. Human Vaccines & Immunotherapeutics
- Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future
- (2013) Johan Holst et al. Human Vaccines & Immunotherapeutics
- Prospects for eradication of meningococcal disease
- (2012) Simon Nadel ARCHIVES OF DISEASE IN CHILDHOOD
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
- (2012) Nicoletta Gossger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
- (2012) María Elena Santolaya et al. LANCET
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
- (2012) Peter C Richmond et al. LANCET INFECTIOUS DISEASES
- Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
- (2012) Eva Hong et al. VACCINE
- The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
- (2011) Daniela Toneatto et al. Human vaccines & immunotherapeutics
- Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults
- (2011) Edson D. Moreira et al. Human vaccines & immunotherapeutics
- The changing and dynamic epidemiology of meningococcal disease
- (2011) Scott A. Halperin et al. VACCINE
- Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates
- (2010) Alan Kimura et al. Clinical and Vaccine Immunology
- Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine
- (2010) J. Lucidarme et al. Clinical and Vaccine Immunology
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
- (2010) H. Campbell et al. Clinical and Vaccine Immunology
- Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
- (2010) Jamie Findlow et al. CLINICAL INFECTIOUS DISEASES
- Meningococcal carriage by age: a systematic review and meta-analysis
- (2010) Hannah Christensen et al. LANCET INFECTIOUS DISEASES
- Serogroup B meningococcal vaccines—an unfinished story
- (2010) Manish Sadarangani et al. LANCET INFECTIOUS DISEASES
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
- (2010) J. Donnelly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
- (2010) Marzia M. Giuliani et al. VACCINE
- Morbidity, mortality and spatial distribution of meningococcal disease, 1974–2007
- (2009) M. HOWITZ et al. EPIDEMIOLOGY AND INFECTION
- Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
- (2009) Caroline L Trotter et al. Expert Review of Vaccines
- Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine
- (2009) Sharon H. Wong et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease
- (2009) Susanne Jacobsson et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now